Adimmune Corporation is a prominent player in the vaccine and biologics industry, recognized for its commitment to high-quality production and innovative solutions tailored to meet diverse customer needs. The company operates multiple technology platforms that facilitate the development and manufacturing of vaccines, including a one-stop filling and packaging service, regulatory support, and market entry assistance. Adimmune's collaborative development process emphasizes resilience in vaccine supply, particularly in response to global health challenges, as evidenced by its engagement with the WHO Pandemic Influenza Preparedness Framework. This strategic partnership underscores the company's dedication to ensuring timely access to vaccines during health emergencies.

One of Adimmune's notable advancements is the EnVAX-A71 vaccine, developed by its subsidiary Enimmune Corp., which has demonstrated a remarkable efficacy of 99.21% in Phase III clinical trials against enterovirus 71 (EV71). This vaccine is particularly significant given the prevalence of EV71 in Asia and its association with severe neurological complications in children. Adimmune's use of a high-yield manufacturing process and cell culture bioreactors positions it to significantly increase production capacity for EnVAX-A71, with plans to expand its market reach into Southeast Asia and China. The company's ongoing efforts to enhance its product pipeline and strategic partnerships reflect its ambition to address pressing health needs and solidify its position in the global vaccine market.

Taiwan

Adimmune Corp (4142) is a biotechnology company based out of Taichung City, Taiwan.

Adimmune

Company Details